Bringing the fundamentals into focus…
Back to Supernus Pharmaceuticals, Inc.
How Supernus Pharmaceuticals, Inc. stacks up
SUPN · against 445 other Healthcare companies of similar size
Valuation
53/ 100
Below the middle of the pack.
Ranked #220 of 446 · scores higher than 50% of peers
Bars: peers in each 10-point band of the valuation score37 peers with a valuation score of 50–59, including SUPN · Click a bar to see the companies
Why valuation scores 53?
Weighted metrics compared with all Healthcare companies.A mix: stronger EBITDA yield, but weaker earnings yield than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -6.7% vs peer median 1.5%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.1% vs peer median 0.0%
- more operating profit (EBITDA) for the company's total value: stronger than 75% of peers. EBITDA yield: 8.5% vs peer median 4.0%
Metric by metric
Position: dot = SUPN, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SUPN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 434 reported | -6.8% | 1.5% | 20% | 30% | |
| EBITDA yieldHigher is better · 447 reported | 8.5% | 4.3% | 73% | 50% | |
| Free cash flow yieldHigher is better · 201 reported | 1.1% | -0.5% | 61% | 20% | |
| Book yieldHigher is better · 436 reported | 63.0% | 36.9% | 74% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around SUPNScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score